NCT02103478 2024-08-27Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)Astex Pharmaceuticals, Inc.Phase 1/2 Completed130 enrolled 34 charts 1 FDA